Clinical Trials

Closed to enrollment

Inclusion Criteria

• Prospective cohort patients
  • Diagnosis date must occur on or after March 24, 2011 (date of ipilimumab approval in US)
  • Has diagnosis of stage III (unresectable) or stage IV (metastatic) melanoma (includes mucosal, uveal acral-lentiginous, leptomeningeal disease)
  • Age ≥ 18 years at time of entry into study
  • Must be actively receiving or scheduled to receive systemic treatment of any line, eg, first, second, third line [including investigational drugs]
    • For patients initiating new treatment, treatment must be started within 28 days after signing informed consent
    • For patients currently receiving treatment, patients must enroll within the first 21 days of starting new treatment
• Retrospective cohort patients
  • Has diagnosis of confirmed unresectable stage III or stage IV  metastatic melanoma (including mucosal, uveal, acral-lentiginous, leptomeningeal disease)
  • Age ≥ 18 years at time of unresectable or metastatic melanoma diagnosis
  • Initiated therapy for unresectable or metastatic melanoma within 4 years prior to approval of ipilimumab (first immune checkpoint inhibitor therapy approved in US)
    • March 25, 2007 - March 24, 2011
    • One year of follow-up data is required from date of therapy initiation
    • If patient passed away within the one year of follow-up they are still eligible and the date of death will be collected
    • If retrospective patients have at least one year of follow-up data and are then treated with immuno-oncology, immune checkpoint inhibitor therapy, or targeted therapy, these patients will be analyzed separately

Exclusion Criteria

• Prospective patients
• Are participating in a clinical study that does not allow enrollment into a non interventional study or clinical studies in which the investigational treatment is blinded
• Started new treatment > 21 days prior to enrollment
• Enrolled in study but did not initiate treatment before 28 days
• Have current malignancies (except non-melanoma skin cancer and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast) that require additional systemic therapy